Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Basourakos SP, Lewicki PJ, Ramaswamy A, Cheng E, Dudley V, Yu M, et al. Clipless Robotic-assisted Radical Prostatectomy and Impact on Outcomes. Eur Urol Focus. 2021.

Sangiorgio VF, Nam A, Chen Z, Orazi A, Tam W. GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms. Leuk Res. 2021;100:106495.

O'Leary MK, Chen SS, Westblade LF, Alabi CA. Design of a PEGylated Antimicrobial Prodrug with Species-Specific Activation. Biomacromolecules. 2021;22(2):984-992.

Buckholz A, Kaplan A, Jessurun J, De Jong Y, Crawford C. Microthrombosis associated with GI bleeding in COVID-19. Gastrointest Endosc. 2021;93(1):263-264.

Iyengar NM, Zhou XK, Mendieta H, El-Hely O, Giri DD, Winston L, et al. Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations. NPJ Breast Cancer. 2021;7(1):18.

Perez VA, Husain S, Magro CM, Strom MA, Williams KM, Levin LE. A newly described cutaneous reaction at sites of insulin pump use in a child with Type 1 diabetes. Pediatr Dermatol. 2021;38(1):239-241.

Jacob RP, Flynn J, Devlin SM, Maloy M, Giralt SA, Maslak P, et al. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts. Transplant Cell Ther. 2021;27(8):697.e1-697.e5.

Manning DK, Shivdasani P, Koeller DR, Schwartz A, Rana HQ, Garber JE, et al. Assessment of genomic alterations in non-syndromic von Hippel-Lindau: Insight from integrating somatic and germline next generation sequencing genomic data. Data Brief. 2021;39:107653.

Sakunrangsit N, Metheepakornchai P, Kumpunya S, Greenblatt MB, Leelahavanichkul A, Pisitkun P, et al. Etanercept prevents TNF-α mediated mandibular bone loss in FcγRIIb-/- lupus model. PLoS One. 2021;16(4):e0250215.

Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828-2837.